A second-generation TKI should always be used as initial therapy for CML
نویسندگان
چکیده
منابع مشابه
Which TKI should be recommended as initial treatment for CML in chronic phase?
The lessons learned from the specifically ”targeted” treatment of patients with chronic myeloid leukemia (CML) using imatinib (Gleevec) are now being applied with sometimes dramatic success in a variety of other tumors in which critical driving mutations have been identified, including some, such as malignant melanoma and lung cancer, that are notoriously resistant to other treatments. Sadly, b...
متن کاملOptimizing tolerability of TKI therapy in CML.
Bosutinib is a dual SRC and ABL1 inhibitor with a unique binding mode that accommodates several BCR-ABL1 mutations that confer TKI resistance to imatinib, nilotinib, or dasatinib. In distinction to other inhibitors, bosutinib does not inhibit the platelet-derived growth factor (PDGF) receptors or KIT which might be associated with an individual safety profile. The design of the bosutinib phase ...
متن کاملPenicillamine should not be used as initial therapy in Wilson's disease.
I feel honored to be asked by the Movement Disorders journal to contribute my thoughts to the controversy on how to treat patients with Wilson’s disease, particularly during the initial period. I am doubly honored to cross swords on this topic with Professor John Walshe, who has contributed so much to the treatment of Wilson’s disease. As I have said in other settings, a whole generation of pat...
متن کاملShould gene therapy be used for newborns with hemophilia?
Hemophilia results from a deficiency of blood coagulation factors and leads to spontaneous bleeding. The disease is an attractive model for gene therapy because small amounts of the deficient protein can reduce the risk of bleeding. Therapeutic levels of coagulation Factor VIII (deficient in hemophilia A) and Factor IX (hemophilia B) have been achieved in mice and dogs, and five gene therapy tr...
متن کاملShould beta-blockers still be used as initial antihypertensive agents in uncomplicated hypertension?
Beta-blockers have long being used as first-line therapy for hypertension as their use had resulted in a reduction in cardiovascular morbidity and mortality in controlled clinical trials. A recent meta-analysis comparing beta-blockers to all other anti-hypertensive drugs taken together has found that stroke reduction was sub-optimal. Specifically, atenolol was associated with a 26% higher risk ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood Advances
سال: 2018
ISSN: 2473-9529,2473-9537
DOI: 10.1182/bloodadvances.2018018655